JP2019533645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533645A5 JP2019533645A5 JP2019514781A JP2019514781A JP2019533645A5 JP 2019533645 A5 JP2019533645 A5 JP 2019533645A5 JP 2019514781 A JP2019514781 A JP 2019514781A JP 2019514781 A JP2019514781 A JP 2019514781A JP 2019533645 A5 JP2019533645 A5 JP 2019533645A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- agents
- protein nanocage
- nanocage
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 72
- 102000004169 proteins and genes Human genes 0.000 claims description 72
- 239000002091 nanocage Substances 0.000 claims description 62
- 239000003814 drug Substances 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 239000003607 modifier Substances 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 10
- 239000000032 diagnostic agent Substances 0.000 claims description 10
- 229940039227 diagnostic agent Drugs 0.000 claims description 10
- 230000000069 prophylactic effect Effects 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 229960003048 vinblastine Drugs 0.000 claims description 10
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 8
- 239000000164 antipsychotic agent Substances 0.000 claims description 6
- -1 bronchial dilators Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 102000008857 Ferritin Human genes 0.000 claims description 4
- 108050000784 Ferritin Proteins 0.000 claims description 4
- 238000008416 Ferritin Methods 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 229940035676 analgesics Drugs 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 claims description 2
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- PEJLNXHANOHNSU-UHFFFAOYSA-N acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride Chemical compound [Cl-].C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21.C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 PEJLNXHANOHNSU-UHFFFAOYSA-N 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001220 amsacrine Drugs 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940125713 antianxiety drug Drugs 0.000 claims description 2
- 239000000924 antiasthmatic agent Substances 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940005529 antipsychotics Drugs 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 229940125716 antipyretic agent Drugs 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 239000002830 appetite depressant Substances 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 229940125692 cardiovascular agent Drugs 0.000 claims description 2
- 239000002327 cardiovascular agent Substances 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 229960000605 dexrazoxane Drugs 0.000 claims description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 2
- 229960005156 digoxin Drugs 0.000 claims description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 229940052760 dopamine agonists Drugs 0.000 claims description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000004083 gastrointestinal agent Substances 0.000 claims description 2
- 229940127227 gastrointestinal drug Drugs 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 150000007857 hydrazones Chemical class 0.000 claims description 2
- 239000003326 hypnotic agent Substances 0.000 claims description 2
- 230000000147 hypnotic effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 239000003149 muscarinic antagonist Substances 0.000 claims description 2
- 229940035363 muscle relaxants Drugs 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- 239000004090 neuroprotective agent Substances 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 239000000734 parasympathomimetic agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229960004838 phosphoric acid Drugs 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 239000000021 stimulant Substances 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395852P | 2016-09-16 | 2016-09-16 | |
| US62/395,852 | 2016-09-16 | ||
| PCT/US2017/052079 WO2018053434A1 (en) | 2016-09-16 | 2017-09-18 | Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533645A JP2019533645A (ja) | 2019-11-21 |
| JP2019533645A5 true JP2019533645A5 (enExample) | 2020-10-08 |
Family
ID=60002019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514781A Pending JP2019533645A (ja) | 2016-09-16 | 2017-09-18 | 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11090391B2 (enExample) |
| EP (1) | EP3512563A1 (enExample) |
| JP (1) | JP2019533645A (enExample) |
| WO (1) | WO2018053434A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108503704A (zh) * | 2017-02-27 | 2018-09-07 | 昆山新蕴达生物科技有限公司 | 穿越血脑屏障的纳米药物载体 |
| CN112367974A (zh) * | 2018-05-15 | 2021-02-12 | DNALite治疗学公司 | 粘液穿透肽、递送媒介和治疗方法 |
| US20210402000A1 (en) * | 2018-10-10 | 2021-12-30 | University Of Washington | High-polymer-density bioconjugate compositions and related methods |
| US20220177547A1 (en) * | 2019-03-07 | 2022-06-09 | Kyungpook National University Industry-Academic Cooperation Foundation | Ferritin nanocage for multi-displaying trail trimer and cancer-targeting peptide and use thereof as anticancer agent |
| WO2021045210A1 (ja) * | 2019-09-05 | 2021-03-11 | 味の素株式会社 | ペプチド内包フェリチン |
| EP4053157A4 (en) * | 2019-11-01 | 2023-12-27 | Cellemedy Co., Ltd | PROTEIN FUSED WITH A DISEASE ANTIGEN AND CORRESPONDING USE |
| JP7541390B2 (ja) * | 2019-11-01 | 2024-08-28 | セレメディー カンパニー，リミテッド | 免疫チェックポイント分子と結合可能な分子が融合したタンパク質およびその用途 |
| WO2021086158A1 (ko) * | 2019-11-01 | 2021-05-06 | (주)셀레메디 | 질환 항원이 융합된 단백질 및 이의 용도 |
| KR102658825B1 (ko) * | 2020-10-23 | 2024-04-19 | 경북대학교 산학협력단 | Pd-l1 결합 펩타이드 1을 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도 |
| CN112972421B (zh) * | 2021-02-26 | 2022-04-08 | 清华大学 | 基于多正电荷蛋白的纳米药物系统、其制备方法及应用 |
| CN115160559B (zh) * | 2021-04-02 | 2024-02-02 | 杭州宜生医药科技发展有限公司 | 一种peg化雷帕霉素化合物及其制备方法与应用 |
| WO2024228598A1 (ko) * | 2023-05-04 | 2024-11-07 | 경북대학교 산학협력단 | Lag3 결합 펩타이드를 융합한 페리틴 나노케이지 및 이의 항암면역치료제로서의 용도 |
| CN119326734B (zh) * | 2024-12-17 | 2025-06-06 | 浙江大学 | 一种铁蛋白纳米颗粒及其药物递送系统的组装方法和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US6699475B1 (en) | 1987-09-02 | 2004-03-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| KR920003787B1 (ko) | 1990-03-05 | 1992-05-14 | 한국과학기술 연구원 | 신규 플라스미드 제조 및 그를 함유한 균주를 배양하여 아이 지 에프-1(igf-1)을 생산하는 방법 |
| US5571711A (en) | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
| US5821122A (en) | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
| AU770643B2 (en) | 1998-08-28 | 2004-02-26 | Uropath Pty Ltd | Method of diagnosis of prostate cancer |
| ATE328280T1 (de) | 1999-02-26 | 2006-06-15 | Pacific Northwest Res Inst | Verfahren und zusammensetzungen zur karzinomdiagnose |
| US6673545B2 (en) | 2000-07-28 | 2004-01-06 | Incyte Corporation | Prostate cancer markers |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US20070258889A1 (en) * | 2005-11-09 | 2007-11-08 | Montana State University | Novel nanoparticles and use thereof |
| WO2007114946A2 (en) | 2006-04-04 | 2007-10-11 | The Regents Of The University Of California | Acid-sensitive linkers for drug delivery |
| NZ594510A (en) | 2006-12-27 | 2012-06-29 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| WO2009073533A2 (en) | 2007-11-30 | 2009-06-11 | Medarex, Inc. | Anti-b7h4 monoclonal antibody-drug conjugate and methods of use |
| WO2010029947A1 (ja) * | 2008-09-09 | 2010-03-18 | 国立大学法人京都大学 | 造影剤組成物及びその製造方法 |
| CA2828253C (en) * | 2011-02-25 | 2016-10-18 | South Dakota State University | Polymer conjugated protein micelles |
| BR112014014262A2 (pt) * | 2011-12-14 | 2017-06-13 | Univ Johns Hopkins | nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas. |
| CA2921493A1 (en) | 2012-08-21 | 2014-02-27 | Brown University | Ferritin-based tumor targeting agent, and imaging and treatment methods |
| US11202820B2 (en) * | 2014-09-25 | 2021-12-21 | Nanyang Technological University | Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages |
-
2017
- 2017-09-18 JP JP2019514781A patent/JP2019533645A/ja active Pending
- 2017-09-18 EP EP17778028.5A patent/EP3512563A1/en not_active Withdrawn
- 2017-09-18 US US16/333,501 patent/US11090391B2/en active Active
- 2017-09-18 WO PCT/US2017/052079 patent/WO2018053434A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533645A5 (enExample) | ||
| AU2021282425B2 (en) | Bioorthogonal compositions | |
| EP3606559B1 (en) | Bioorthogonal compositions | |
| CN103796684B (zh) | 大分子 | |
| US20180085321A1 (en) | Solid nanoparticle with inorganic coating | |
| CA3202226A1 (en) | Compositions of peptide inhibitors of interleukin-23 receptor | |
| JPWO2020122034A5 (enExample) | ||
| JP2012532185A5 (enExample) | ||
| WO2016206540A1 (zh) | 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质 | |
| JP2008529539A5 (enExample) | ||
| JP2015519330A5 (enExample) | ||
| JP2009500431A5 (enExample) | ||
| JP7102005B2 (ja) | 改善されたハイブリッドテロデンドリマー | |
| JP2013512889A5 (enExample) | ||
| JP2011505345A5 (enExample) | ||
| JP2013535505A5 (enExample) | ||
| US20210100910A1 (en) | Macromolecules | |
| JP2017119721A (ja) | 併用療法用ナノ粒子 | |
| AU2019383466A1 (en) | Therapeutic dendrimer | |
| JP2016509586A5 (enExample) | ||
| Hou et al. | Spatial targeting of fibrosis-promoting macrophages with nanoscale metal-organic frameworks for idiopathic pulmonary fibrosis therapy | |
| CN103044686A (zh) | 一种混合结构plga-pll-peg靶向多聚物载体的制备及其应用 | |
| US11564995B2 (en) | Peptide-nanoparticle conjugates | |
| JP2023500602A (ja) | ペプチド－ナノ粒子コンジュゲート 〔関連出願の相互参照〕 本出願は、２０１９年１０月２９日に出願されたｐｃｔ／ｕｓ２０１９／０５８４６３の一部継続出願であり、２０１９年１０月２９日に出願された米国仮出願第６２／９２７，２９３号の優先権を主張し、その全体が参照により本明細書に組み込まれる。 | |
| CN111373246A (zh) | 包括硼替佐米的聚合物纳米颗粒 |